Abstract
Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
Keywords: Cancer gene therapy, measles virus clinical trials, MV-CEA, MV-NIS, oncolytic measles, virotherapy.
Current Cancer Drug _targets
Title:Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Volume: 18 Issue: 2
Author(s): Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, Kah Whye Peng, Mark J. Federspiel, Stephen J. Russell and Evanthia Galanis*
Affiliation:
- Department of Molecular Medicine, Mayo Clinic 200 First Street SW, Rochester, MN 55905,United States
Keywords: Cancer gene therapy, measles virus clinical trials, MV-CEA, MV-NIS, oncolytic measles, virotherapy.
Abstract: Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
Export Options
About this article
Cite this article as:
Msaouel Pavlos, Opyrchal Mateusz, Dispenzieri Angela, Peng Whye Kah, Federspiel J. Mark, Russell J. Stephen and Galanis Evanthia*, Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects, Current Cancer Drug _targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170222125035
DOI https://dx.doi.org/10.2174/1568009617666170222125035 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug _targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and _targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug _targets. These include, but ...read more
Innovative Drug Research Propelling a New Era of Precision Oncology
Drug-oncology research is leading a new era of precision medicine, becoming a frontier hotspot in cancer treatment. Advancements in molecular biology, genomics, and medicinal chemistry have driven revolutionary changes in cancer cognition and treatment strategies. Gene-_targeted drugs provide more precise treatments, improving survival rates for certain cancers. Network pharmacology offers ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action of DNA-Damaging Anticancer Drugs in Treatment of Carcinomas: Is Acute Apoptosis an “Off-_target” Effect?
Mini-Reviews in Medicinal Chemistry Recent Developments of _targeted Therapies in the Treatment of Non-Small Cell Lung Cancer
Current Drug Discovery Technologies Computational Approach to the Discovery of Phytochemical Molecules with Therapeutic Potential _targets to the PKCZ protein
Letters in Drug Design & Discovery Novel and Emerging _targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug _targets (Discontinued) Personalized & Precision Medicine in Cancer: A Theranostic Approach
Current Radiopharmaceuticals The Tumor Stroma as Mediator of Drug Resistance - A Potential _target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Airway Stents: Current Practice and Future Directions
Current Respiratory Medicine Reviews JDHY3 Inhibits Hypopharyngeal Carcinoma Cell Proliferation and Promotes Apoptosis by Inhibiting the PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry Honey Against Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. An Umbrella Review of Systematic Reviews and Meta- Analyses of the Literature
Reviews on Recent Clinical Trials Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Substrate Specificity of Rat DESC4, a Type II Transmembrane Serine Protease
Protein & Peptide Letters Emerging Family of Protein-protein Interaction Inhibitors _targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Integrin Function and Signaling as Pharmacological _targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies